The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Management of Hepatocellular Carcinoma: An Update Δσ
Open accessAbstract
Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged that requires that the guidelines be updated. The full version of the new guidelines is available on the AASLD Web site at http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/HCCUpdate2010.pdf. Here, we briefly describe only new or changed recommendations. AASLD, American Association for the Study of Liver Diseases; BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma. In the previous guideline, groups were specified for which surveillance was likely to be cost-effective because the hepatocellular carcinoma (HCC) incidence was high enough. New data on defining HCC risk have emerged for hepatitis B virus,1, 2 hepatitis C virus,3 and autoimmune hepatitis.4 Surveillance is deemed cost-effective if the expected HCC risk exceeds 1.5% per year in patients with hepatitis C and 0.2% per year in patients with hepatitis B. Analysis of recent studies show that alpha-fetoprotein determination lacks adequate sensitivity and specificity for effective surveillance (and for diagnosis).5, 6 Thus, surveillance has to be based on ultrasound examination. The recommended screening interval is 6 months. Diagnosis of HCC should be based on imaging techniques and/or biopsy.The 2005 diagnostic algorithm has been validated and the diagnostic accuracy of a single dynamic technique showing intense arterial uptake followed by "washout" of contrast in the venous-delayed phases has been demonstrated.7-9 Contrast-enhanced US may offer false positive HCC diagnosis in patients with cholangiocarcinoma and thus, has been dropped from the diagnostic techniques. The diagnostic algorithm is shown in Fig. 1. The application of dynamic imaging criteria should be applied only to patients with cirrhosis of any etiology and to patients with chronic hepatitis B who may not have fully developed cirrhosis or have regressed cirrhosis. Interpretation of biopsies and distinction between high-grade dysplatic nodules and HCC is challenging. Expert pathology diagnosis is reinforced by staining for glypican 3, heat shock protein 70, and glutamine synthetase, because positivity for two of these three stains confirms HCC.10 Diagnostic algorithm for suspected HCC. CT, computed tomography; MDCT, multidetector CT; MRI, magnetic resonance imaging; US, ultrasound. The BCLC staging system (Fig. 2)11 has come to be widely accepted in clinical practice and is also being used for many clinical trials of new drugs to treat HCC. Therefore, it has become the de facto staging system that is used. The BCLC staging system for HCC. M, metastasis classification; N, node classification; PS, performance status; RFA, radiofrequency ablation; TACE, transarterial chemoembolization. The recommendations for liver transplantation have not changed. No new data have emerged that can be used to define a new limit for expanding the patient selection criteria. The usefulness of portal pressure measurement to predict the outcome of patients and define optimal candidates for resection has been validated in Japan.12 Thus, resection should remain the first option for patients who have the optimal profile, as defined by the BCLC staging system. Although resection can be performed in some of these patients with advanced liver disease, the mortality is higher and they might be better served by liver transplantation or ablation. A cohort study of radiofrequency ablation demonstrated that complete ablation of lesions smaller than 2 cm is possible in more than 90% of cases, with a local recurrence rate of less than 1%.13 These data should be confirmed by other groups before positioning ablation as the first-line approach for very early HCC. The recommendations regarding patient selection and method of administration of chemoembolization are unchanged. Radioembolization, i.e., the intra-arterial injection of yttrium-90 bound to glass beads or to resin, has been shown to induce tumor necrosis, but there are no data comparing its efficacy to transarterial chemoembolization or to sorafenib treatment for those with portal vein invasion. However, for patients who have either failed transarterial chemoembolization or who present with more advanced HCC, new data indicates the efficacy of sorafenib (a multikinase inhibitor with activity against Raf-1, B-Raf, vascular endothelial growth factor receptor 2, platelet-derived growth factor receptor, c-Kit receptors, among other kinases) in prolonging life.14, 15 Sorafenib induces a clinically relevant improvement in time to progression and in survival The magnitude of the improvement in survival compares with other established molecular targeted therapies for other advanced cancers, and the associated toxicity is easily managed without treatment-related mortality. The most frequent adverse events were diarrhea (sorafenib ve
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects
Forner, A., Reig, M. E., Rodriguez de Lope, C., & Bruix, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247133 · Cited by 1,110
Self-citationLivraghi, T., Meloni, F., Di Stasi, M., Rolle, E., Solbiati, L., Tinelli, C., & Rossi, S. (2008) · Hepatology · doi:10.1002/hep.21933 · Cited by 1,103
Forner, A., Vilana, R., Ayuso, C., Bianchi, L., Solé, M., Ayuso, J. R., Boix, L., Sala, M., Varela, M., Llovet, J. M., et al. (2008) · Hepatology · doi:10.1002/hep.21966 · Cited by 1,032
Self-citationSINGAL, A., VOLK, M. L., WALJEE, A., SALGIA, R., HIGGINS, P., ROGERS, M. A. M., & MARRERO, J. A. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04014.x · Cited by 819
Ishizawa, T., Hasegawa, K., Aoki, T., Takahashi, M., Inoue, Y., Sano, K., Imamura, H., Sugawara, Y., Kokudo, N., & Makuuchi, M. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.091 · Cited by 754
Lok, A. S., Seeff, L. B., Morgan, T. R., di Bisceglie, A. M., Sterling, R. K., Curto, T. M., Everson, G. T., Lindsay, K. L., Lee, W. M., Bonkovsky, H. L., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.09.014 · Cited by 651
Cited by
Items 101–200 of 233
Changing Hepatocellular Carcinoma Incidence and Liver Cancer Mortality Rates in the United States
Altekruse, S. F., Henley, J. S., Cucinelli, J. E., & McGlynn, K. A. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.11 · Cited by 429
DNA methylation‐based prognosis and epidrivers in hepatocellular carcinoma
Villanueva, A., Portela, A., Sayols, S., Battiston, C., Hoshida, Y., Méndez‐González, J., Imbeaud, S., Letouzé, E., Hernandez‐Gea, V., Cornella, H., et al. (2015) · Hepatology · doi:10.1002/hep.27732 · Cited by 428
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Llovet, J. M., Villanueva, A., Marrero, J. A., Schwartz, M., Meyer, T., Galle, P. R., Lencioni, R., Greten, T. F., Kudo, M., Mandrekar, S. J., et al. (2021) · Hepatology · doi:10.1002/hep.31327 · Cited by 413
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.045 · Cited by 419
Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers
Wang, Y., & Deng, B. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10084-4 · Cited by 415
D'Ambrosio, R., Aghemo, A., Rumi, M. G., Ronchi, G., Donato, M. F., Paradis, V., Colombo, M., & Bedossa, P. (2012) · Hepatology · doi:10.1002/hep.25606 · Cited by 409
El‐Serag, H. B., Kanwal, F., Richardson, P., & Kramer, J. (2016) · Hepatology · doi:10.1002/hep.28535 · Cited by 411
Viral hepatitis and liver cancer
Ringehan, M., McKeating, J. A., & Protzer, U. (2017) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2016.0274 · Cited by 410
Qin, S., Bi, F., Gu, S., Bai, Y., Chen, Z., Wang, Z., Ying, J., Lu, Y., Meng, Z., Pan, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00163 · Cited by 409
Cucchetti, A., Piscaglia, F., Cescon, M., Colecchia, A., Ercolani, G., Bolondi, L., & Pinna, A. D. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.009 · Cited by 407
Primovist, Eovist: What to expect?
Van Beers, B. E., Pastor, C. M., & Hussain, H. K. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.01.031 · Cited by 407
Sun, Y.-F., Xu, Y., Yang, X.-R., Guo, W., Zhang, X., Qiu, S.-J., Shi, R.-Y., Hu, B., Zhou, J., & Fan, J. (2013) · Hepatology · doi:10.1002/hep.26151 · Cited by 404
A MELD-Based Model to Determine Risk of Mortality Among Patients With Acute Variceal Bleeding
Reverter, E., Tandon, P., Augustin, S., Turon, F., Casu, S., Bastiampillai, R., Keough, A., Llop, E., González, A., Seijo, S., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.10.018 · Cited by 402
Trinchet, J.-C., Chaffaut, C., Bourcier, V., Degos, F., Henrion, J., Fontaine, H., Roulot, D., Mallat, A., Hillaire, S., Cales, P., et al. (2010) · Hepatology · doi:10.1002/hep.24545 · Cited by 400
Immune checkpoint therapy in liver cancer
Xu, F., Jin, T., Zhu, Y., & Dai, C. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0777-4 · Cited by 397
Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations
Nault, J.-C., Sutter, O., Nahon, P., Ganne-Carrié, N., & Séror, O. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.004 · Cited by 395
Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines
Ayuso, C., Rimola, J., Vilana, R., Burrel, M., Darnell, A., García-Criado, Á., Bianchi, L., Belmonte, E., Caparroz, C., Barrufet, M., et al. (2018) · European Journal of Radiology · doi:10.1016/j.ejrad.2018.01.025 · Cited by 394
Self-citationKorean Liver Cancer Association, K., & National Cancer Center, N. (2019) · Gut and Liver · doi:10.5009/gnl19024 · Cited by 391
Kokudo, N., Hasegawa, K., Akahane, M., Igaki, H., Izumi, N., Ichida, T., Uemoto, S., Kaneko, S., Kawasaki, S., Ku, Y., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12464 · Cited by 391
Ringe, K. I., Husarik, D. B., Sirlin, C. B., & Merkle, E. M. (2010) · American Journal of Roentgenology · doi:10.2214/ajr.10.4392 · Cited by 388
Agren, R., Mardinoglu, A., Asplund, A., Kampf, C., Uhlen, M., & Nielsen, J. (2014) · Molecular Systems Biology · doi:10.1002/msb.145122 · Cited by 387
Berzigotti, A., Reig, M., Abraldes, J. G., Bosch, J., & Bruix, J. (2015) · Hepatology · doi:10.1002/hep.27431 · Cited by 385
Self-citationMarrero, J. A., Kudo, M., Venook, A. P., Ye, S.-L., Bronowicki, J.-P., Chen, X.-P., Dagher, L., Furuse, J., Geschwind, J.-F. H., de Guevara, L. L., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.020 · Cited by 385
Xia, H., Ooi, L. L. P. J., & Hui, K. M. (2013) · Hepatology · doi:10.1002/hep.26369 · Cited by 378
Renzulli, M., Brocchi, S., Cucchetti, A., Mazzotti, F., Mosconi, C., Sportoletti, C., Brandi, G., Pinna, A. D., & Golfieri, R. (2016) · Radiology · doi:10.1148/radiol.2015150998 · Cited by 376
Kim, Y.-S., Lim, H. K., Rhim, H., Lee, M. W., Choi, D., Lee, W. J., Paik, S. W., Koh, K. C., Lee, J. H., Choi, M. S., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.09.020 · Cited by 372
Sapisochin, G., Facciuto, M., Rubbia‐Brandt, L., Marti, J., Mehta, N., Yao, F. Y., Vibert, E., Cherqui, D., Grant, D. R., Hernandez‐Alejandro, R., et al. (2016) · Hepatology · doi:10.1002/hep.28744 · Cited by 370
Self-citationSapisochin, G., Goldaracena, N., Laurence, J. M., Dib, M., Barbas, A., Ghanekar, A., Cleary, S. P., Lilly, L., Cattral, M. S., Marquez, M., et al. (2016) · Hepatology · doi:10.1002/hep.28643 · Cited by 368
Mechanisms of drug resistance in HCC
Ladd, A. D., Duarte, S., Sahin, I., & Zarrinpar, A. (2024) · Hepatology · doi:10.1097/hep.0000000000000237 · Cited by 363
Kim, S. Y., An, J., Lim, Y.-S., Han, S., Lee, J.-Y., Byun, J. H., Won, H. J., Lee, S. J., Lee, H. C., & Lee, Y. S. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3147 · Cited by 356
Nault, J. C., Calderaro, J., Di Tommaso, L., Balabaud, C., Zafrani, E. S., Bioulac‐Sage, P., Roncalli, M., & Zucman‐Rossi, J. (2014) · Hepatology · doi:10.1002/hep.27372 · Cited by 354
Johnson, P. J., Pirrie, S. J., Cox, T. F., Berhane, S., Teng, M., Palmer, D., Morse, J., Hull, D., Patman, G., Kagebayashi, C., et al. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0870 · Cited by 350
Treatment of Patients with Cirrhosis
Ge, P. S., & Runyon, B. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1504367 · Cited by 348
Hirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315259 · Cited by 362
Deep learning reconstruction improves image quality of abdominal ultra-high-resolution CT
Akagi, M., Nakamura, Y., Higaki, T., Narita, K., Honda, Y., Zhou, J., Yu, Z., Akino, N., & Awai, K. (2019) · European Radiology · doi:10.1007/s00330-019-06170-3 · Cited by 346
Sieghart, W., Hucke, F., Pinter, M., Graziadei, I., Vogel, W., Müller, C., Heinzl, H., Trauner, M., & Peck-Radosavljevic, M. (2013) · Hepatology · doi:10.1002/hep.26256 · Cited by 343
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007
Petrick, J. L., Braunlin, M., Laversanne, M., Valery, P. C., Bray, F., & McGlynn, K. A. (2016) · International Journal of Cancer · doi:10.1002/ijc.30211 · Cited by 342
Mazzaferro, V., Citterio, D., Bhoori, S., Bongini, M., Miceli, R., De Carlis, L., Colledan, M., Salizzoni, M., Romagnoli, R., Antonelli, B., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30224-2 · Cited by 341
Poulou, L. S. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i8.1054 · Cited by 340
Heterogeneity of liver cancer and personalized therapy
Li, L., & Wang, H. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.07.018 · Cited by 339
Liver Resection and Surgical Strategies for Management of Primary Liver Cancer
Orcutt, S. T., & Anaya, D. A. (2018) · Cancer Control · doi:10.1177/1073274817744621 · Cited by 337
Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma
Chang, Y., Jeong, S. W., Young Jang, J., & Jae Kim, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218165 · Cited by 336
Transarterial chemoembolization: Modalities, indication, and patient selection
Sieghart, W., Hucke, F., & Peck-Radosavljevic, M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.010 · Cited by 336
Treatment of Hepatocellular Carcinoma: A Systematic Review
Lin, S., Hoffmann, K., & Schemmer, P. (2012) · Liver Cancer · doi:10.1159/000343828 · Cited by 334
Yin, L., Li, H., Li, A.-J., Lau, W. Y., Pan, Z.-Y., Lai, E. C. H., Wu, M.-C., & Zhou, W.-P. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.03.012 · Cited by 334
Stine, J. G., Wentworth, B. J., Zimmet, A., Rinella, M. E., Loomba, R., Caldwell, S. H., & Argo, C. K. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14937 · Cited by 336
Ng, K. K. C., Chok, K. S. H., Chan, A. C. Y., Cheung, T. T., Wong, T. C. L., Fung, J. Y. Y., Yuen, J., Poon, R. T. P., Fan, S. T., & Lo, C. M. (2017) · British Journal of Surgery · doi:10.1002/bjs.10677 · Cited by 331
Dimitroulis, D., Damaskos, C., Valsami, S., Davakis, S., Garmpis, N., Spartalis, E., Athanasiou, A., Moris, D., Sakellariou, S., Kykalos, S., et al. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i29.5282 · Cited by 330
Simmons, O., Fetzer, D. T., Yokoo, T., Marrero, J. A., Yopp, A., Kono, Y., Parikh, N. D., Browning, T., & Singal, A. G. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13841 · Cited by 328
Berhane, S., Toyoda, H., Tada, T., Kumada, T., Kagebayashi, C., Satomura, S., Schweitzer, N., Vogel, A., Manns, M. P., Benckert, J., et al. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.12.042 · Cited by 323
Tang, A., Bashir, M. R., Corwin, M. T., Cruite, I., Dietrich, C. F., Do, R. K. G., Ehman, E. C., Fowler, K. J., Hussain, H. K., Jha, R. C., et al. (2018) · Radiology · doi:10.1148/radiol.2017170554 · Cited by 319
Wang, Z., Ren, Z., Chen, Y., Hu, J., Yang, G., Yu, L., Yang, X., Huang, A., Zhang, X., Zhou, S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2899 · Cited by 318
Wang, Y.-Y., Zhong, J.-H., Su, Z.-Y., Huang, J.-F., Lu, S.-D., Xiang, B.-D., Ma, L., Qi, L.-N., Ou, B.-N., & Li, L.-Q. (2016) · British Journal of Surgery · doi:10.1002/bjs.10095 · Cited by 318
Radioembolization for hepatocellular carcinoma
Sangro, B., Iñarrairaegui, M., & Bilbao, J. I. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.07.012 · Cited by 315
Medical therapies for hepatocellular carcinoma: a critical view of the evidence
Villanueva, A., Hernandez-Gea, V., & Llovet, J. M. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.199 · Cited by 314
Vouche, M., Habib, A., Ward, T. J., Kim, E., Kulik, L., Ganger, D., Mulcahy, M., Baker, T., Abecassis, M., Sato, K. T., et al. (2014) · Hepatology · doi:10.1002/hep.27057 · Cited by 311
Yin, J., Li, N., Han, Y., Xue, J., Deng, Y., Shi, J., Guo, W., Zhang, H., Wang, H., Cheng, S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5896 · Cited by 307
Singal, A. G., Mukherjee, A., Elmunzer, J. B., Higgins, P. D. R., Lok, A. S., Zhu, J., Marrero, J. A., & Waljee, A. K. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.332 · Cited by 305
Pawlik, T. M., Reyes, D. K., Cosgrove, D., Kamel, I. R., Bhagat, N., & Geschwind, J.-F. H. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.1021 · Cited by 304
Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review
Daher, S., Massarwa, M., Benson, A. A., & Khoury, T. (2018) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00031 · Cited by 304
Vietti Violi, N., Duran, R., Guiu, B., Cercueil, J.-P., Aubé, C., Digklia, A., Pache, I., Deltenre, P., Knebel, J.-F., & Denys, A. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30029-3 · Cited by 302
Sapisochin, G., Barry, A., Doherty, M., Fischer, S., Goldaracena, N., Rosales, R., Russo, M., Beecroft, R., Ghanekar, A., Bhat, M., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.022 · Cited by 301
Precision diagnosis and treatment of liver cancer in China
Fu, J., & Wang, H. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.10.008 · Cited by 301
Qi, L.-N., Xiang, B.-D., Wu, F.-X., Ye, J.-Z., Zhong, J.-H., Wang, Y.-Y., Chen, Y.-Y., Chen, Z.-S., Ma, L., Chen, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2459 · Cited by 301
Cancer and liver cirrhosis: implications on prognosis and management
Pinter, M., Trauner, M., Peck-Radosavljevic, M., & Sieghart, W. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000042 · Cited by 295
Cancer surveillance in patients with primary sclerosing cholangitis
Razumilava, N., Gores, G. J., & Lindor, K. D. (2011) · Hepatology · doi:10.1002/hep.24570 · Cited by 292
Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma
Sauzay, C., Petit, A., Bourgeois, A.-M., Barbare, J.-C., Chauffert, B., Galmiche, A., & Houessinon, A. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.10.006 · Cited by 291
Utilization of Hepatocellular Carcinoma Surveillance Among American Patients: A Systematic Review
Singal, A. G., Yopp, A., S. Skinner, C., Packer, M., Lee, W. M., & Tiro, J. A. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-011-1952-x · Cited by 288
Best, J., Bechmann, L. P., Sowa, J.-P., Sydor, S., Dechêne, A., Pflanz, K., Bedreli, S., Schotten, C., Geier, A., Berg, T., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.11.012 · Cited by 288
Pompili, M., Saviano, A., de Matthaeis, N., Cucchetti, A., Ardito, F., Federico, B., Brunello, F., Pinna, A. D., Giorgio, A., Giulini, S. M., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.03.009 · Cited by 285
Dhir, M., Melin, A. A., Douaiher, J., Lin, C., Zhen, W. (., Hussain, S. M., Geschwind, J.-F. H., Doyle, M. B. M., Abou-Alfa, G. K., & Are, C. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001556 · Cited by 285
Wei, X., Jiang, Y., Zhang, X., Feng, S., Zhou, B., Ye, X., Xing, H., Xu, Y., Shi, J., Guo, W., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02184 · Cited by 285
Liver cancer: Approaching a personalized care
Bruix, J., Han, K.-H., Gores, G., Llovet, J. M., & Mazzaferro, V. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.007 · Cited by 284
Self-citationCurrent epidemiology in hepatocellular carcinoma
Konyn, P., Ahmed, A., & Kim, D. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1991792 · Cited by 280
Wong, G. L.-H., Chan, H. L.-Y., Wong, C. K.-Y., Leung, C., Chan, C. Y., Ho, P. P.-L., Chung, V. C.-Y., Chan, Z. C.-Y., Tse, Y.-K., Chim, A. M.-L., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.09.029 · Cited by 280
Recent advances in hepatocellular carcinoma therapy
Dutta, R., & Mahato, R. I. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.010 · Cited by 280
Hameed, B., Mehta, N., Sapisochin, G., Roberts, J. P., & Yao, F. Y. (2014) · Liver Transplantation · doi:10.1002/lt.23904 · Cited by 279
Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria
Tirkes, T., Hollar, M. A., Tann, M., Kohli, M. D., Akisik, F., & Sandrasegaran, K. (2013) · RadioGraphics · doi:10.1148/rg.335125214 · Cited by 279
Lin, X.-J., Chong, Y., Guo, Z.-W., Xie, C., Yang, X.-J., Zhang, Q., Li, S.-P., Xiong, Y., Yuan, Y., Min, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00048-0 · Cited by 276
Edeline, J., Boucher, E., Rolland, Y., Vauléon, E., Pracht, M., Perrin, C., Le Roux, C., & Raoul, J. (2012) · Cancer · doi:10.1002/cncr.26255 · Cited by 275
Prognostic factors and prevention of radioembolization-induced liver disease
Gil-Alzugaray, B., Chopitea, A., Iñarrairaegui, M., Bilbao, J. I., Rodriguez-Fraile, M., Rodriguez, J., Benito, A., Dominguez, I., D'Avola, D., Herrero, J. I., et al. (2013) · Hepatology · doi:10.1002/hep.26191 · Cited by 275
Cabrera, R. (2012) · Hepatic Medicine: Evidence and Research · doi:10.2147/hmer.s16316 · Cited by 274
van der Meer, A. J., Feld, J. J., Hofer, H., Almasio, P. L., Calvaruso, V., Fernández-Rodríguez, C. M., Aleman, S., Ganne-Carrié, N., D’Ambrosio, R., Pol, S., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.10.017 · Cited by 274
Yu, S. J. (2016) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2016.22.1.7 · Cited by 273
Wang, C., Wang, H., Yang, W., Hu, K., Xie, H., Hu, K., Bai, W., Dong, Z., Lu, Y., Zeng, Z., et al. (2015) · Hepatology · doi:10.1002/hep.27548 · Cited by 272
Chemotherapy for hepatocellular carcinoma: current status and future perspectives
Ikeda, M., Morizane, C., Ueno, M., Okusaka, T., Ishii, H., & Furuse, J. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyx180 · Cited by 272
Fuks, D., Dokmak, S., Paradis, V., Diouf, M., Durand, F., & Belghiti, J. (2012) · Hepatology · doi:10.1002/hep.24680 · Cited by 268
Atiq, O., Tiro, J., Yopp, A. C., Muffler, A., Marrero, J. A., Parikh, N. D., Murphy, C., McCallister, K., & Singal, A. G. (2017) · Hepatology · doi:10.1002/hep.28895 · Cited by 266
Serper, M., Taddei, T. H., Mehta, R., D’Addeo, K., Dai, F., Aytaman, A., Baytarian, M., Fox, R., Hunt, K., Goldberg, D. S., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.02.040 · Cited by 265
Comparison of hepatocellular carcinoma in Eastern versus Western populations
Choo, S. P., Tan, W. L., Goh, B. K. P., Tai, W. M., & Zhu, A. X. (2016) · Cancer · doi:10.1002/cncr.30237 · Cited by 264
Kim, J. H., Kim, Y. D., Lee, M., Jun, B. G., Kim, T. S., Suk, K. T., Kang, S. H., Kim, M. Y., Cheon, G. J., Kim, D. J., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.07.018 · Cited by 264
Golfieri, R., Cappelli, A., Cucchetti, A., Piscaglia, F., Carpenzano, M., Peri, E., Ravaioli, M., D'Errico-Grigioni, A., Pinna, A. D., & Bolondi, L. (2011) · Hepatology · doi:10.1002/hep.24246 · Cited by 264
Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems
Liu, P.-H., Hsu, C.-Y., Hsia, C.-Y., Lee, Y.-H., Su, C.-W., Huang, Y.-H., Lee, F.-Y., Lin, H.-C., & Huo, T.-I. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.029 · Cited by 263
Chan, A. W. H., Chan, S. L., Wong, G. L. H., Wong, V. W. S., Chong, C. C. N., Lai, P. B. S., Chan, H. L. Y., & To, K.-F. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4516-1 · Cited by 263
Altekruse, S. F., McGlynn, K. A., Dickie, L. A., & Kleiner, D. E. (2012) · Hepatology · doi:10.1002/hep.24710 · Cited by 262
Villa, E., Critelli, R., Lei, B., Marzocchi, G., Cammà, C., Giannelli, G., Pontisso, P., Cabibbo, G., Enea, M., Colopi, S., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-308483 · Cited by 262
Davenport, M. S., Viglianti, B. L., Al-Hawary, M. M., Caoili, E. M., Kaza, R. K., Liu, P. S. C., Maturen, K. E., Chenevert, T. L., & Hussain, H. K. (2013) · Radiology · doi:10.1148/radiol.12120826 · Cited by 262
Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review
Axley, P., Ahmed, Z., Ravi, S., & Singal, A. K. (2018) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00067 · Cited by 262
Mittal, S., Sada, Y. H., El-Serag, H. B., Kanwal, F., Duan, Z., Temple, S., May, S. B., Kramer, J. R., Richardson, P. A., & Davila, J. A. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.08.013 · Cited by 261
Metadata
- Authors
- Bruix, J., & Sherman, M.
- Venue
- Hepatology
- Published
- 2011-03
- Volume
- 53
- Issue
- 3
- Pages
- 1020-1022
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2163403599
- Cited by
- 8,103
- References
- 15
- FWCI
- 350.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.